Company intelligence / Profile preview
Immorna
Hangzhou, Zhejiang, Chinaimmorna.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Immorna has received multiple IND clearances from both the US FDA and China NMPA. Its lead program JCXH-211—a self-replicating mRNA encoding IL‑12—has shown excellent safety/tolerability and significant anti-tumor activity in early clinical data. The company also recently dosed its first patient with JCXH‑213, an mRNA-based in vivo CAR therapy. It has received a grant from the Bill & Melinda Gates Foundation to support its RSV vaccine clinical development.[1][4]
- Therapeutic areas
- OncologyRare DiseasesDermatologyInfectious Diseases
- Modalities
- mRNA-based therapeutics and vaccinesConventional mRNASelf-replicating RNA (srRNA)Circular RNA
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Bill & Melinda Gates Foundation grant for RSV vaccine development[1]
Beyond the preview
Go deeper on Immorna.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immorna.